University of Florida
Gainesville, Florida, 32608, United States
NCT Number: NCT06868238
The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary lymph node staging through use of a traditional sentinel lymph node biopsy (SLNB) procedure where the lymph nodes that drain the breast first are removed at the time of mastectomy. This recommendation for traditional SLNB is due to the risk of finding invasive cancer during surgical evaluation of the mastectomy specimen and the inability to accurately map the lymphatic channels once the breast is removed.
In a study by Herremans et al, the majority of traditional SLNBs were demonstrated to be unnecessary. By using Magtrace, a novel iron based lymphatic mapping agent, a delayed SLNB could eliminate these unnecessary traditional SLNBs.
Magtrace, or superparamagnetic oxide (SPIO), was developed in 2018. Unlike traditional mapping agents of blue dye and technetium that clear the body within 24-48 hours, Magtrace remains in the lymph nodes for at least 4 weeks. Magtrace's ability to remain in the lymph node allows accurate mapping of the lymph nodes at the time of the mastectomy with the ability to return to the operating room for a delayed sentinel lymph node biopsy if invasive cancer is found on final pathology.
This study will investigate whether the use of Magtrace will successfully allow patients with DCIS undergoing mastectomy to avoid undergoing SLNB.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Gainesville, Florida, 32608, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
o The mastectomy can be with or without reconstruction and with or without contralateral prophylactic mastectomy.
Exclusion criteria
Participants will receive a single injection of Magtrace into the breast during their mastectomy.
Time frame: 24 months post-mastectomy
Determine the percentage of patients with DCIS who do not undergo sentinel lymph node biopsy.
Time frame: At the time of mastectomy
Determine the Percentage of patients that are found to have invasive disease at time of mastectomy.
Time frame: 24 months post-mastectomy
Determine the number of patients who return to the operating room for delayed sentinel lymph node biopsy.
Time frame: 24 months post-mastectomy
Compare the scores obtained to the historical control for each of the following scales of the Breast-Q questionnaire: psychosocial well-being, sexual well-being, cancer worry, fatigue, and impact on work.
University of Florida
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06033092
ATM Gene Mutation, Adenocarcinoma
Genoa, Italy
View Trial DetailsNCT06903468
Adenocarcinoma, Breast Cancer
Gainesville, Florida, United States
View Trial DetailsNCT06902311
Adenocarcinoma, Breast Cancer
Chapel Hill, North Carolina, United States
View Trial DetailsNCT06218303
Adenocarcinoma, Breast Carcinoma In Situ
Pittsburgh, Pennsylvania, United States
View Trial Details